The Prevalence of Bacterial and Fungal Coinfections among Critically Ill COVID-19 Patients in the ICU in Jordan
- PMID: 36353524
- PMCID: PMC9640228
- DOI: 10.1155/2022/9992881
The Prevalence of Bacterial and Fungal Coinfections among Critically Ill COVID-19 Patients in the ICU in Jordan
Abstract
Background: Secondary bacterial and fungal coinfections have been reported among critically ill coronavirus disease-19 (COVID-19) patients and are associated with increased disease severity and mortality incidence (MI) rates.
Aims: This study aimed to track bacterial and fungal coinfections among COVID-19 patients in the intensive care unit (ICU) and to assess the impact of these infections on disease prognosis and patient outcomes in Jordan.
Materials and methods: This was a single-center study that enrolled 46 ICU patients diagnosed with COVID-19. Microbiological and antimicrobial susceptibility results and inflammatory biomarker data were retrospectively analyzed.
Results: The MI rate attributed to bacterial and fungal coinfections was 84.8%, and the highest rate was reported among patients older than 70 years (66.7%). The MI rate related to bacterial coinfections was 95.2%, whereas that of fungal coinfections was 4.8%. The most commonly isolated bacterium in the blood was a coagulase-negative staphylococcus (41%), followed by Klebsiella pneumoniae in nasopharyngeal swabs (34%) and Acinetobacter baumannii in sputum samples (31%). Candida species were the sole cause of fungal coinfections in the studied population. In particular, Candida albicans was isolated from 3% of patients with bacteremia, whereas Candida glabrata was isolated from 8% of nasopharyngeal swabs. Klebsiella pneumoniae was considered the major cause of upper respiratory tract infections (34%). Multifactorial infection was significantly associated with increased MI (p value <0.001).
Conclusion: COVID-19 MI is associated with respiratory bacterial/fungal coinfections. The ability to predict bacterial and fungal coinfections in ICU patients may be crucial to their survival and prognosis.
Copyright © 2022 Ayman Daifallah Alsheikh et al.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Respiratory co-infections in COVID-19-positive patients.Eur J Med Res. 2023 Sep 2;28(1):317. doi: 10.1186/s40001-023-01305-1. Eur J Med Res. 2023. PMID: 37660059 Free PMC article.
-
Incidence of Bacterial and Fungal Secondary Infections in COVID-19 Patients Admitted to the ICU.Int J Gen Med. 2022 Sep 24;15:7475-7485. doi: 10.2147/IJGM.S382687. eCollection 2022. Int J Gen Med. 2022. PMID: 36187162 Free PMC article.
-
Bacterial and fungal coinfections among patients with COVID-19 in Zanjan, Northwest of Iran; a single-center observational with meta-analysis of the literature.Iran J Microbiol. 2022 Oct;14(5):624-635. doi: 10.18502/ijm.v14i5.10955. Iran J Microbiol. 2022. PMID: 36531818 Free PMC article.
-
Global Coinfections with Bacteria, Fungi, and Respiratory Viruses in Children with SARS-CoV-2: A Systematic Review and Meta-Analysis.Trop Med Infect Dis. 2022 Nov 15;7(11):380. doi: 10.3390/tropicalmed7110380. Trop Med Infect Dis. 2022. PMID: 36422931 Free PMC article. Review.
-
State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia.Infection. 2021 Aug;49(4):591-605. doi: 10.1007/s15010-021-01602-z. Epub 2021 Mar 11. Infection. 2021. PMID: 33709380 Free PMC article. Review.
Cited by
-
Acinetobacter baumannii infection in critically ill patients with COVID-19 from Tehran, Iran: the prevalence, antimicrobial resistance patterns and molecular characteristics of isolates.Front Cell Infect Microbiol. 2025 Jan 30;14:1511122. doi: 10.3389/fcimb.2024.1511122. eCollection 2024. Front Cell Infect Microbiol. 2025. PMID: 39958989 Free PMC article.
-
Candidemia Following Severe COVID-19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta-Analysis.Mycoses. 2024 Oct;67(10):e13798. doi: 10.1111/myc.13798. Mycoses. 2024. PMID: 39379339
-
Blood Stream Infections in COVID-19 Patients From a Tertiary Care Center in Lebanon: Causative Pathogens and Rates of Multi-Drug Resistant Organisms.Mayo Clin Proc Innov Qual Outcomes. 2023 Nov 24;7(6):556-568. doi: 10.1016/j.mayocpiqo.2023.10.001. eCollection 2023 Dec. Mayo Clin Proc Innov Qual Outcomes. 2023. PMID: 38075430 Free PMC article.
References
LinkOut - more resources
Full Text Sources